Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China. Issue 39 (1st October 2021)

• Record Type: Journal Article
• Authors: Jiang, Zhi-guo; Liao, Shao-Guang
• Other Names: Huang. Shu-Pin section editor.
• Is Part Of: Medicine. Volume 100:Issue 39(2021)
• Publication Date: 2021-10-01
• Subjects: neutrophil-to-lymphocyte ratio -- Castration-resistant prostate cancer -- outcomes; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000027361
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The aim of this study is to investigate the association between baseline neutrophil-to-lymphocyte ratio (NLR) and progression-free survival (PFS), overall survival (OS) and radiological response in castration-resistant prostate cancer patients treated with docetaxel. Forty-one prostate cancer patients who were treated with docetaxel were selected. Univariable and multivariable Cox regression models were used to predict the association of baseline NLR as a dichotomous variable with PFS and OS after chemotherapy initiation. In Kaplan–Meier analysis, the median PFS (9.8 vs 7.5 months, P = .039, Fig. 1 ) and OS (17.6 vs 14.2 months, P = .021, Fig. 2 ) was higher in patients who did not have an elevated NLR than in those with an elevated NLR. In univariate analysis, the pretreatment NLR was significantly associated with PFS ( P = .049) and OS ( P = .023). In multivariable analysis, patients with a NLR of >3 were at significantly higher risk of tumor progress (hazard ratio 2.458; 95% confidence interval 1.186–5.093; P = .016) and death (hazard ratio 3.435; 95% CI 1.522–7.750; P = .003)than patients with a NLR of ⩽3. NLR may be an independent predictor of PFS and OS in castration-resistant prostate cancer patients treated with docetaxel. The findings require validation in further prospective, big sample-sized studies.